Danila Daniel C, Zhang Xun, Zhou Yunli, Haidar Jaafar N Sleiman, Klibanski Anne
Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
J Clin Endocrinol Metab. 2002 Oct;87(10):4741-6. doi: 10.1210/jc.2002-020527.
Activin is a member of the TGF beta family of cytokines involved in the control of cell proliferation. We have previously shown that the majority of clinically nonfunctioning pituitary tumors do not respond to activin-induced growth suppression. Human pituitary tumors specifically express alternatively spliced activin type I receptor Alk4 mRNAs, producing C-terminus truncated isoforms designated Alk4-2, 4-3, and 4-4. However, it is not known whether these truncated activin receptors suppress activin effects on cell proliferation in human pituitary cells. Therefore, we investigated activin signaling in a human pituitary tumor cell line, HP75, derived from a clinically nonfunctioning pituitary tumor. HP75 cells express activin A mRNA and secrete activin A, as measured by ELISA and a functional bioassay. TGF beta administration decreases the proliferation of HP75 cells, suggesting that the signaling pathway shared by TGF beta and activin is functional in this cell line. However, activin neither inhibits cell proliferation nor stimulates reporter gene expression in HP75 cells, indicating that activin signaling is specifically blocked at the receptor level. HP75 cells express all truncated activin type I receptor Alk4 isoforms, as determined by RT-PCR. Because truncated Alk4 receptor isoforms inhibit activin signaling by competing with the wild-type receptor for binding to activin type II receptors, we hypothesized that overexpression of wild-type activin type I receptor will restore activin signaling. In HP75 cells, cotransfection of the wild-type activin type I receptor Alk4-1 expression vector increases activin-responsive reporter activity. Furthermore, transfection with wild-type activin receptor type I results in activin-mediated suppression of cell proliferation. These data indicate that truncated Alk4 isoforms interfere with activin signaling pathways and thereby may contribute to uncontrolled cell growth. Overexpression of the wild-type Alk4-1 receptor restores responsiveness to activin in human pituitary tumor-derived cells.
激活素是参与细胞增殖调控的细胞因子转化生长因子β(TGFβ)家族的成员。我们之前已经表明,大多数临床上无功能的垂体瘤对激活素诱导的生长抑制无反应。人类垂体瘤特异性表达可变剪接的激活素I型受体Alk4 mRNA,产生C末端截短的异构体,命名为Alk4-2、4-3和4-4。然而,尚不清楚这些截短的激活素受体是否会抑制激活素对人垂体细胞增殖的影响。因此,我们在源自临床上无功能垂体瘤的人垂体瘤细胞系HP75中研究了激活素信号传导。通过酶联免疫吸附测定(ELISA)和功能性生物测定法测量,HP75细胞表达激活素A mRNA并分泌激活素A。给予TGFβ可降低HP75细胞的增殖,这表明TGFβ和激活素共有的信号通路在该细胞系中起作用。然而,激活素既不抑制HP75细胞的增殖,也不刺激其报告基因表达,这表明激活素信号传导在受体水平被特异性阻断。通过逆转录聚合酶链反应(RT-PCR)测定,HP75细胞表达所有截短的激活素I型受体Alk4异构体。由于截短的Alk4受体异构体通过与野生型受体竞争结合激活素II型受体来抑制激活素信号传导,我们推测野生型激活素I型受体的过表达将恢复激活素信号传导。在HP75细胞中,野生型激活素I型受体Alk4-1表达载体的共转染增加了激活素反应性报告基因活性。此外,用野生型I型激活素受体转染导致激活素介导的细胞增殖抑制。这些数据表明截短的Alk4异构体干扰激活素信号通路,从而可能导致细胞生长失控。野生型Alk4-1受体的过表达恢复了人垂体瘤来源细胞对激活素的反应性。